Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...

Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, ...

Novo has enjoyed a tremendous windfall of $46 billion in net profit since mid-2021, when Wegovy became the first highly effective obesity treatment approved in the United States ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...

Hims & Hers stock plunged around 30% on Monday after drugmaker Novo Nordisk abruptly ended a month-long collaboration to make ...

The Howard County Board of Education is suing Eli Lilly and Co., Novo Nordisk, CVS, UnitedHealth Group and several other drug manufacturers accusing the companies of deliberately inflating insulin ...

In a statement, Novo Nordisk said that it was terminating the collaboration "due to concerns about their illegal mass ...

Novo Nordisk ends partnership with Hims & Hers over safety and marketing concerns tied to compounded Wegovy, as rivalry with ...

The global health landscape is evolving with Brazil battling bird flu-related trade restrictions, Nestle USA eliminating ...

On April 29, Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on ...